$1.13
+0.09 (+8.65%)
Open$1.05
Previous Close$1.04
Day High$1.16
Day Low$1.05
52W High$43.81
52W Low$22.05
Volume—
Avg Volume119.7K
Market Cap11.40M
P/E Ratio41.96
EPS$0.75
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,513.3% upside
Current
$1.13
$1.13
Target
$40.83
$40.83
$24.77
$40.83 avg
$47.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.91M | 2.02M | 1.51M |
| Net Income | 293.8K | 234.8K | 245.0K |
| Profit Margin | 15.4% | 11.6% | 16.3% |
| EBITDA | 387.2K | 368.8K | 310.9K |
| Free Cash Flow | 223.2K | 168.2K | 121.5K |
| Rev Growth | +14.6% | +14.4% | +1.3% |
| Debt/Equity | 0.46 | 0.35 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |